# Donidalorsen Treatment in Children With Hereditary Angioedema

> **NCT07298447** · PHASE3 · RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** Donidalorsen

## Key facts

- **NCT ID:** NCT07298447
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298447, "Donidalorsen Treatment in Children With Hereditary Angioedema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07298447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*